In adults with cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced the primary composite cardiovascular end point versus placebo.
In plain wordsIn adults with heart disease and overweight but no diabetes, semaglutide cut the rate of heart attack, stroke or cardiovascular death compared with placebo.
- Peptide
- Semaglutide
- Outcome
- DecreaseComposite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke
- Study
n = 17,604
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- 2.4 mg once weekly · subcutaneousAs given in this study (human).
Measurements
- primary end-point event rate
- 6.5%
- semaglutide
- primary end-point event rate
- 8%
- placebo
- hazard ratio
- 0.8 ratio
- semaglutide vs placebo
Source sentences
A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).
2 context sentences(design, population, supporting numbers)
In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but…
Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo.